A study presented at the San Antonio Breast Cancer Symposium showed that the multikinase inhibitor Tinengotinib exhibited activity among heavily pretreated patients with hormone receptor-positive, HER2-negative breast cancer or those with triple-negative disease. The majority of patients in the study experienced treatment-related adverse events, but they were manageable. Efficacy results included objective responses and clinical benefit rates in both patient groups. The study included data from two trials that evaluated Tinengotinib for patients with hormone receptor-positive, HER2-negative breast cancer or triple-negative breast cancer who had no available standard treatment. The study found that the agent showed activity and manageable adverse effects in heavily pretreated patients with breast cancer.
Source link
Tinengotinib exhibits activity in pretreated breast cancer
